Contract Analytical Services Whether it is for routine analytical release testing or the development of challenging or specialized analytical methods for your large or small molecule, Intellipharmaceutics’ team of highly experienced analytical will meet your quality standards. Analytical Services At Intellipharmaceutics, we are engaged in the research, development and commercialization of pharmaceutical products, both novel and generic, with a particular emphasis in the controlled-release & opioid abuse deterrence space. A Pipeline that Spans from NDAs to ANDAs Our product portfolio includes both new products, which follow a New Drug Application (NDA) 505(b)(2) FDA regulatory pathway, and controlled-release generic products, and cover therapeutic areas that range from neurology, cardiovascular, gastrointestinal tract, diabetes and pain. We have developed several drug delivery systems and a pipeline of products (some of which have received FDA approval) and product candidates in various stages of development, including ANDAs filed with the FDA (and one ANDS filed with Health Canada) and one NDA filing. PRODUCT PIPELINE NEWS & EVENTS Intellipharmaceutics Announces Fiscal Year 2020 Results Intellipharmaceutics Reports Director Election Results Intellipharmaceutics Announces Change in Venue for The Company’s Annual General Meeting Scheduled To Be Held on December 23, 2020 Investor Relations Press Releases Stock Data Financial Results SEC Filings SEDAR Filings Corporate Profile Contract Drug Development, Analytical Services & Abuse Deterrent Studies PARTNER NOW © Copyright 2020 Intellipharmaceutics International Inc. All Right Reserved.